Home

CARYSIL — Deck

Carysil Ltd · CARYSIL · NSE

A Gujarat quartz-sink exporter trading at 28x earnings and 198x free cash flow — margin recovery or working-capital trap

₹906
CMP (52W: ₹582–₹1,072)
₹2,577 Cr
Market Cap
28.5x
P/E (TTM)
17.3%
FY25 EBITDA Margin (was 22% in FY22)
~80% exports (UK 40%, US 21%, India 21%), 10 quarters of rebuild since FY22 peak, 9M FY26 profit already above full-year FY25
1 · Business

German-technology quartz sink exporter dressed up as an Indian consumer durable

  • Quartz sinks (48% of revenue). 1M-unit global capacity, 65% utilised; sole supplier to Karran USA (~150k units) with IKEA and GROHE behind it.
  • Geography. UK 40%, USA 21%, India 21%, rest 18% — Carysil is a tariff-and-freight play wearing an Indian small-cap label.
  • India optionality (₹170 Cr). 4,000+ dealers, ₹500 Cr medium-term target — premium branded sales carry 2–3x the margin of OEM export.
Moat is a cost position on quartz (India labour + Schock-derived technology), not a brand — durable until a Chinese or Turkish exporter closes the gap.
2 · Numbers

Margin recovery is real — but ₹611 Cr of capex produced almost no incremental net income

17.3%
FY25 EBITDA Margin (was 21.7% in FY22)
15.4%
FY25 ROCE (was 27% in FY22)
290
Inventory Days (was 184 in FY23)
₹13 Cr
FY25 Free Cash Flow (₹64 Cr reported profit)

Revenue compounded 20% for 11 years but net income has flatlined at ₹53–65 Cr since FY22 — depreciation and interest from the capex cycle ate the operating leverage. 9M FY26 profit (₹71 Cr) already beats full-year FY25.

3 · People

Grade B — founder with ₹780 Cr of stock, but NRC compliance fine and thin bench

  • Promoter MD Chirag Parekh. 23 years on board, ~30% direct equity, zero pledge; a one-principal company with the CFO as the only other executive director.
  • Pay tension. MD package ₹7.89 Cr is ~14% of standalone PAT — required a LODR Schedule V special resolution in FY23.
  • NRC penalty (FY25). NSE and BSE each fined Carysil for an NRC-composition lapse under LODR Reg 19(1); statutory auditor carries a qualifying note.
  • Promise-vs-delivery. ₹1,000 Cr FY25 target slipped to ₹816 Cr; recent quarters show tighter, more granular, capacity-linked guidance.
Risk Management Committee is chaired by the MD himself — he is marking his own homework on risk.
4 · Story

From Acrysil OEM to Carysil brand — the five-year reset after COVID euphoria

FY21–FY22 (the COVID tailwind). US renovation boom pushed quartz volumes up 44% and EBITDA to 22%; NSE listing, Acrysil renamed Carysil, management promised ₹1,000 Cr by FY25 and four bolt-on acquisitions were layered on top (Tap Warehouse UK, United Granite US, Sternhagen, Turkey).

FY23–FY26 (the reset). Destocking, Red Sea freight and a loss-making US subsidiary compressed margins 500bps; a ₹125 Cr July-2024 QIP recapitalised the balance sheet just as IKEA non-US RFQ tripled wallet share and Karran rolled sinks into 1,800 Lowe's stores. Margins back to 19%, debt ₹312→₹235 Cr.

The inflection was the QIP — without it, Carysil hit the 2025 US tariff shock over-levered and capacity-constrained.
5 · Risks

Four material risks — all independent, none currently priced in

  • US tariff concentration. 21% of revenue via Karran USA; any renegotiation of the bilateral 18% deal or loss of the Karran sole-source hits revenue and utilisation in the same quarter.
  • Working capital trap. Inventory days 184→290 (FY23→FY25); ~₹250 Cr locked in finished sinks — if it doesn't unwind by Q4 FY26, write-down risk sits behind the narrative.
  • Customer concentration. CMD disclosed US+IKEA+Karran are now >60% of quartz revenue; the RFQ wins deepened dependency rather than diversifying it.
  • Key-person & succession. Chirag Parekh is the entire strategy, sales and investor face; no declared #2 beyond the CFO, senior-most Independent Director exits Mar 2026.
Cash conversion cycle has nearly doubled since FY22 — this is the single most important balance-sheet item to watch.
6 · What's Next

Q4 FY26 print in May is the thesis gate — three gates, two have to pass

  • May 2026 — Q4 FY26 earnings. Op margin ≥19%, inventory days ≤250, and 9M quartz utilisation commentary; miss any two and stock derates to ₹650–₹750.
  • April 2026 — Carysil 2.0 domestic expo. Management unveils the ₹500 Cr India 'vision document' — specific capacity-linked targets would restore credibility; another top-down number would not.
  • H2 FY26 — IKEA non-US RFQ ramp. Moulds commissioned, 3x wallet-share award already announced; execution visible in Q1 FY27 print.
  • Ongoing — India-US 18% bilateral tariff. Any renegotiation or escalation resets the whole US-exposure calculus; discounts already rolled back in Q3 FY26.
  • Mar 2026 — Independent Director transition. Senior-most ID Dr. Sonal Ambani exits; replacement signals whether the board gets stronger or weaker.
The single thing the market will watch: inventory days on the May balance sheet — it tells you whether FY26 margin recovery is real or funded off the balance sheet.
7 · For & Against

Lean constructive — the margin recovery is printing, but the multiple already assumes ROCE goes back to 22%

  • For. 9M FY26 NI (₹71 Cr) already beats full-year FY25; three straight quarters of 19% op margin validates the FY22-peak recovery path (Quant).
  • For. IKEA 3x wallet share + Karran–Lowe's 1,800-store rollout = genuine, contract-level external validation, not narrative (Warren, Historian).
  • For. Founder with ₹780 Cr personal stock, zero pledge, QIP deployed on capacity not enrichment, debt ₹312→₹235 Cr (Sherlock).
  • Against. ₹611 Cr cumulative capex produced ₹540 Cr of incremental revenue and essentially no incremental net income — ROCE halved from 27% to 15% (Quant).
  • Against. 198x P/FCF on FY25, 52x on 3-yr avg FCF — at Cera-like multiples with 30% lower ROCE, the market is pre-paying for FY27 mean reversion (Quant).
  • Against. ₹1,000 Cr FY25 target missed by 18%, ₹500 Cr domestic target slipped two years, NRC compliance fine in FY25 — promise-delivery is improving but not clean (Sherlock, Historian).
My View — Lean cautiously constructive. The IKEA/Karran wins are real and margin recovery is in the tape; what tips the scale against is working capital — if Q4 FY26 inventory days stay above 260, the FCF story is structurally broken and the multiple isn't defensible.

Watchlist to re-rate: Q4 FY26 inventory days (target <250), quartz utilisation trajectory toward 80%, Carysil 2.0 domestic unveil in April